文献速递妇科肿瘤

局部晚期宫颈癌诱导化疗后放化疗:GCIG INTERLACE 试验的生活质量结局

Induction chemotherapy followed by chemoradiation in locally advanced cervical cancer: Quality of life outcomes of the GCIG INTERLACE trial.
PubMed 文献 · Eur J Cancer · 2025-03-21

INTERLACE 试验纳入 500 例 FIGO 2008 分期 IB1 淋巴结阳性、IB2、II、IIIB 和 IVA 期宫颈癌女性,随机接受单纯放化疗或诱导化疗(6 周卡铂 AUC2 联合紫杉醇 80mg/m2)后放化疗,采用混合模型比较至随访 2 年的生活质量。结果显示诱导化疗期间总体健康状况、躯体与社会功能轻度变差、情绪功能改善,周围神经病变轻度加重,但两组各症状平均差异均小且未达临床意义阈值(<5 单位),至 12–18 个月消退。

要点

  • 诱导化疗期间总体健康状况、躯体与社会功能轻度变差,情绪功能改善,症状体验轻度改善。
  • 诱导化疗联合放化疗组周围神经病变轻度重于单纯放化疗,疲乏与恶心呕吐在诱导化疗第 4 周较基线加重。
  • 至放化疗后 2 年各症状组间平均评分差异均<5 单位,未达临床相关性阈值。

核心结论

  • 在放化疗基础上加诱导化疗,与单纯放化疗相比,在诱导化疗期间、放化疗期间及之后均未对生活质量产生不利影响。

研究设计与样本

  • GCIG INTERLACE 试验为随机对照试验,纳入 500 例 FIGO 2008 分期 IB1 淋巴结阳性、IB2、II、IIIB 和 IVA 期宫颈癌女性。
  • 受试者随机接受单纯放化疗或诱导化疗(6 周卡铂 AUC2 联合紫杉醇 80mg/m2)后放化疗。
  • 采用 EORTC QLQ-C30 v3 与 QLQ-CX24 问卷在基线、诱导化疗第 4 周第 1 天、放化疗第 1 天、放化疗第 3 周第 1 天、放化疗后 4 周及所有随访时点评估生活质量。
  • 采用重复测量混合模型比较两组自试验治疗至随访 2 年的差异,并校正基线。

主要发现

  • 诱导化疗联合放化疗组不良事件发生率为 99%,单纯放化疗组为 95%;3/4 级不良事件分别为 59% 与 48%。
  • 诱导化疗期间总体健康状况、躯体功能和社会功能轻度变差,症状体验轻度改善,情绪功能改善。
  • 诱导化疗联合放化疗组周围神经病变轻度重于单纯放化疗组。
  • 疲乏和恶心呕吐从基线至诱导化疗第 4 周加重,疼痛和腹泻改善,与报告的不良事件一致。
  • 整个期间上述症状两组平均差异小且无临床意义,至 12–18 个月消退;至放化疗后 2 年各时点平均评分差异均<5 单位,未达临床相关性阈值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: Induction chemotherapy (IC) added to chemoradiation (CRT) in locally advanced cervical cancer (LACC) improves survival at the expense of adverse events (AEs), 99 % with IC/CRT vs 95 % CRT alone, 59 % vs 48 % G3/4 AEs. We investigated the impact of this on quality of life (QoL). METHODS: 500 women with FIGO 2008 stage IB1 node positive, IB2, II, IIIB and IVA cervical carcinoma were randomised to CRT alone or IC (6 weeks carboplatin AUC2 paclitaxel 80mg/m2) followed by CRT. QoL questionnaires (EORTC QLQ-C30 v3, QLQ-CX24) were completed at baseline, D1 week 4 IC, D1 CRT, D1 week 3 CRT, 4 weeks post CRT and all follow up visits. Mixed modelling for repeated measures was used to compare the groups during trial treatment to 2 years follow up (adjusting for baseline). RESULTS: QoL (global health status, physical and social functioning) slightly worsened during IC and symptom experience slightly improved. Emotional functioning improved during IC. Peripheral neuropathy was slightly worse with IC/CRT. Fatigue and nausea/vomiting worsened from baseline to week 4 IC whilst pain and diarrhoea improved, consistent with reported AEs. Over the whole period, mean differences for these symptoms between the treatment groups was small and not clinically significant and resolved by 12-18 months. In all cases, mean score differences during trial treatment until 2 years post CRT showed only small differences (<5 units) not meeting the threshold for clinical relevance. CONCLUSION: IC added to CRT does not adversely impact QoL compared to CRT, either during IC, during CRT or later.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Eminowicz G, Vaja S, Gallardo D, et al. Induction chemotherapy followed by chemoradiation in locally advanced cervical cancer: Quality of life outcomes of the GCIG INTERLACE trial. Eur J Cancer. 2025. PMID: 40139003. doi:10.1016/j.ejca.2025.115375

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。